Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Adenosine - King Pharmaceuticals

Drug Profile

Adenosine - King Pharmaceuticals

Alternative Names: MEDR 640; Pallacor

Latest Information Update: 19 Feb 2001

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Fujisawa; King Pharmaceuticals Research and Development
  • Developer King Pharmaceuticals Research and Development
  • Class Anti-ischaemics; Antiarrhythmics; Purine nucleosides; Ribonucleosides; Small molecules
  • Mechanism of Action Purinergic P1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Postmyocardial infarction

Most Recent Events

  • 19 Feb 2001 Discontinued-III for Postmyocardial infarction in Canada (IV-infusion)
  • 19 Feb 2001 Discontinued-III for Postmyocardial infarction in USA (IV-infusion)
  • 05 Apr 2000 Adenosine - Medco Research is available for licensing (http://www.kingpharm.com/)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top